530 692
[37]
Whiting PF, Rutjes AW, Westwood ME, et al. QUADAS-2: A revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med 2011;155:529–36.
[38]
Moore CM, Kasivisvanathan V, Eggener S, et al. Standards of report- ing for MRI-targeted biopsy studies (START) of the prostate: Recommendations from an international working group. Eur Urol 2013;64:544–52.
[39]
Altman D, MachinD, Bryant T, Gardner M. Statistics with confidence: Confidence intervals and statistical guidelines. ed. 2. London, UK: BMJ Books; 2000.
[40] Higgins JPT, Green S. Cochrane handbook for systematic reviews of
interventions. Version 5.1.0. The Cochrane Collaboration, 2011.
http://handbook.cochrane.org.
[41]
Schoots IG, Roobol MJ, Nieboer D, Bangma CH, Steyerberg EW, Hunink MG. Magnetic resonance imaging-targeted biopsy may enhance the diagnostic accuracy of significant prostate cancer detection compared to standard transrectal ultrasound-guided biopsy: A systematic review and meta-analysis. Eur Urol 2015; 68:438–50.
[42]
Wysock JS, Rosenkrantz AB, Huang WC, et al. A prospective, blinded comparison of magnetic resonance (MR) imaging-ultra- sound fusion and visual estimation in the performance of MR- targeted prostate biopsy: The PROFUS trial. Eur Urol 2014;66: 343–51.
[43]
Wegelin O, van Melick HHE, Somford DM, et al. The future trial: Fusion target biopsy of the prostate using real-time ultrasound and MR images. A multicentre RCT on target biopsy techniques in the diagnosis of prostate cancer. J Clin Trials 2015;5:248.
[44]
Vourganti S, Rastinehad A, Yerram NK, et al. Multiparametric magnetic resonance imaging and ultrasound fusion biopsy detect prostate cancer in patients with prior negative transrectal ultra- sound biopsies. J Urol 2012;188(6):2152–7.
[45]
Shakir NA, George AK, Siddiqui MM, et al. Identification of threshold prostate specific antigen levels to optimize the detection of clini- cally significant prostate cancer by magnetic resonance imaging/ ultrasound fusion guided biopsy. J Urol 2014;192(6):1642–8.
[46]
Peltier A, Aoun F, Lemort M, Kwizera F, Paesmans M, Van Velthoven R. MRI-targeted biopsies versus systematic transrectal ultrasound guided biopsies for the diagnosis of localized prostate cancer in biopsy naive men. Biomed Res Int 2015;2015:571708.
[47]
Quentin M, Blondin D, Arsov C, et al. Prospective evaluation of magnetic resonance imaging guided in-bore prostate biopsy versus systematic transrectal ultrasound guided prostate biopsy in biopsy naive men with elevated prostate specific antigen. J Urol 2014; 192(5):1374–9.
[48]
Radtke JP, Kuru TH, Boxler S, et al. Comparative analysis of trans- perineal template saturation prostate biopsy versus magnetic res- onance imaging targeted biopsy with magnetic resonance imaging- ultrasound fusion guidance. J Urol 2015;193(1):87–94.
[49]
Siddiqui MM, Rais-Bahrami S, Turkbey B, et al. Comparison of MR/ ultrasound fusion-guided biopsy with ultrasound-guided biopsy for the diagnosis of prostate cancer. JAMA 2015;313:390–7.
[50]
Hambrock T, Futterer JJ, Huisman HJ, et al. Thirty-two-channel coil 3T magnetic resonance-guided biopsies of prostate tumor suspi- cious regions identified on multimodality 3T magnetic resonance imaging: technique and feasibility. Invest Radiol 2008;43(10): 686–94.
[51]
Hambrock T, Somford DM, Hoeks C, et al. Magnetic resonance imaging guided prostate biopsy in men with repeat negative biop- sies and increased prostate specific antigen. J Urol 2010;183(2): 520–7.[52]
Miyagawa T, Ishikawa S, Kimura T, et al. Real-time virtual sonog- raphy for navigation during targeted prostate biopsy using mag- netic resonance imaging data. Int J Urol 2010;17(10):855–60.
[53]
Franiel T, Stephan C, Erbersdobler A, et al. Areas suspicious for prostate cancer: MR-guided biopsy in patients with at least one transrectal US-guided biopsy with a negative finding–multipara- metric MR imaging for detection and biopsy planning. Radiology 2011;259(1):162–72.
[54]
Park BK, Park JW, Park SY, et al. Prospective evaluation of 3-T MRI performed before initial transrectal ultrasound-guided prostate biopsy in patients with high prostate-specific antigen and no previous biopsy. AJR Am J Roentgenol 2011;197(5):W876–81.
[55]
Portalez D, Mozer P, Cornud F, et al. Validation of the European Society of Urogenital Radiology scoring system for prostate cancer diagnosis on multiparametric magnetic resonance imaging in a cohort of repeat biopsy patients. Eur Urol 2012;62(6):986–96.
[56]
Rouse P, Shaw G, Ahmed HU, Freeman A, Allen C, Emberton M. Multi-parametric magnetic resonance imaging to rule-in and rule- out clinically important prostate cancer in men at risk: a cohort study. Urol Int 2011;87(1):49–53.
[57]
Arsov C, Quentin M, Rabenalt R, Antoch G, Albers P, Blondin D. Repeat transrectal ultrasound biopsies with additional targeted cores according to results of functional prostate MRI detects high- risk prostate cancer in patients with previous negative biopsy and increased PSA – a pilot study. Anticancer Res 2012;32(3):1087–92.
[58]
Nagel KN, Schouten MG, Hambrock T, et al. Differentiation of prostatitis and prostate cancer by using diffusion-weighted MR imaging and MR-guided biopsy at 3 T. Radiology 2013;267(1): 164–72.
[59]
Quentin M, Schimmoller L, Arsov C, et al. 3-T in-bore MR-guided prostate biopsy based on a scoring system for target lesions char- acterization. Acta Radiol 2013;54(10):1224–9.[60]
Junker D, Schafer G, Edlinger M, et al. Evaluation of the PI-RADS scoring system for classifying mpMRI findings in men with suspi- cion of prostate cancer. Biomed Res Int 2013;2013:252939.
[61]
Rosenkrantz AB, Mussi TC, Borofsky MS, Scionti SS, Grasso M, Taneja SS. 3.0 T multiparametric prostate MRI using pelvic phased-array coil: utility for tumor detection prior to biopsy. Urol Oncol 2013;31(8):1430–5.[62]
Delongchamps NB, Peyromaure M, Schull A, et al. Prebiopsy mag- netic resonance imaging and prostate cancer detection: compari- son of random and targeted biopsies. J Urol 2013;189(2):493–9.
[63]
Fiard G, Hohn N, Descotes JL, Rambeaud JJ, Troccaz J, Long JA. Targeted MRI-guided prostate biopsies for the detection of prostate cancer: initial clinical experience with real-time 3-dimensional transrectal ultrasound guidance and magnetic resonance/transrec- tal ultrasound image fusion. Urology 2013;81(6):1372–8.[64]
Kaufmann S, Kruck S, Kramer U, et al. Direct comparison of targeted MRI-guided biopsy with systematic transrectal ultrasound-guided biopsy in patients with previous negative prostate biopsies. Urol Int 2015;94(3):319–25.
[65]
Penzkofer T, Tuncali K, Fedorov A, et al. Transperineal in-bore 3-T MR imaging-guided prostate biopsy: a prospective clinical obser- vational study. Radiology 2015;274(1):170–80.
[66]
Schimmoller L, Quentin M, Arsov C, et al. MR-sequences for prostate cancer diagnostics: validation based on the PI-RADS scoring system and targeted MR-guided in-bore biopsy. Eur Radiol 2014;24(10): 2582–9.[67]
Mozer P, Roupret M, Le Cossec C, et al. First round of targeted biopsies using magnetic resonance imaging/ultrasonography fusion compared with conventional transrectal ultrasonography- guided biopsies for the diagnosis of localised prostate cancer. BJU Int 2015;115(1):50–7.
[68]
Salami SS, Vira MA, Turkbey B, et al. Multiparametric magnetic resonance imaging outperforms the Prostate Cancer Prevention Trial risk calculator in predicting clinically significant prostate cancer. Cancer 2014;120(18):2876–82.
E U R O P E A N U R O L O G Y 7 1 ( 2 0 1 7 ) 5 1 7 – 5 3 1
530